Kairos Pharma’s encouraging interim safety report for ENV-105 is profoundly overshadowed by the complete absence of efficacy data and a powerful negative precedent for its drug class. While no Grade 3+ serious adverse events in 13 patients is a positive start, this must be weighed against the definitive failure of cetuximab, another anti-EGFR monoclonal antibody, in NSCLC. [1][2] The cetuximab program showed no progression-free survival benefit when added to chemotherapy (PFS 2.9 vs 2.8 months) and resulted in a 41% rate of serious adverse events, leading to a recommendation against its use. [3] Without efficacy data, ENV-105 has not yet demonstrated any differentiation from this failed predecessor. Competitors like amivantamab have succeeded by targeting distinct niches (EGFR exon 20), but ENV-105's strategy in the broader osimertinib-resistant population appears mechanistically similar to cetuximab. [4] Payers will recall this history and will almost certainly require a substantial, statistically significant PFS improvement over standard chemotherapy, as a manageable safety profile alone is insufficient for market access. The program's core risk is that it will replicate cetuximab's futility, making the rapid generation of a compelling efficacy signal the only critical path forward. [2]
The claim rests on uncontrolled safety observations in only 13 patients. No efficacy data is provided to contextualize clinical benefit or overcome the significant negative precedent for this drug class in NSCLC. [5]
| Indication | Advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer |
| Drug | ENV-105 and osimertinib |
| Mechanism of Action | CD105 antibody and EGFR inhibitor |
| Company | Kairos Pharma |
| Trial Phase | Phase I |
| Category | Clinical Trial Event |
| Sub Category | Interim Analysis |
| Therapeutic Area | Oncology |
| Combination Partner Company | AstraZeneca |
| Patient Enrollment | 13 patients |
| Adverse Event Grading Standard | CTCAE 5.0 |
| Osimertinib Annual Sales | $6bn |
| Target Protein for ENV-105 | CD105 |
| Other Indication Under Investigation | Castrate-resistant prostate cancer |
| Other Trial Phase | Phase II |
Kairos Pharma Reports Positive Interim Phase I Safety Data for ENV-105
Kairos Pharma reported interim safety results from its Phase I clinical trial of ENV-105 (carotuximab) combined with AstraZeneca’s Tagrisso (osimertinib) for advanced EGFR-mutated non-small cell lung cancer (NSCLC). The trial, assessing safety, tolerability, and optimal Phase II dosing, has so far shown that none of the 13 treated patients experienced serious adverse events (Grade 3 or higher) related to ENV-105, with other side effects being manageable. This combination targets patients who have developed resistance to osimertinib, the current standard of care.
- The Phase I trial of ENV-105 in combination with osimertinib has established a favorable safety profile, with no serious adverse events (Grade 3 or higher) attributed to ENV-105 among the 13 patients enrolled. All reported side effects were manageable with standard supportive care, confirming the drug's tolerability across different indications, as noted by the Chief Science Officer.
- The combination therapy is specifically designed to address the critical unmet need of patients with advanced EGFR-mutated NSCLC who have developed resistance to osimertinib, the current global standard-of-care. ENV-105 acts by targeting CD105, a protein elevated in osimertinib-resistant patients, aiming to re-sensitize them to EGFR-targeted therapy and change the post-progression treatment paradigm.
- Kairos Pharma aims to position ENV-105 as an "essential complement" to the multi-billion dollar EGFR-targeted therapy market, offering a re-sensitization solution. The positive interim safety data supports the drug's potential to provide better, longer-term patient care and facilitates progression towards determining the recommended Phase II dose, with ongoing evaluation in a separate Phase II trial for castrate-resistant prostate cancer.
Addressing Osimertinib Resistance in EGFR-mutated NSCLC
The most significant limitation in treating advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is the inevitable development of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). This challenge persists across all TKI generations, including the third-generation agent osimertinib, and ultimately curtails the long-term effectiveness of targeted therapy. A complex landscape of resistance mechanisms, both on-target and via bypass pathways, requires ongoing characterization to guide subsequent treatment strategies.
Acquired On-Target Mutations: Resistance to first- and second-generation TKIs is predominantly driven by the secondary EGFR T790M mutation, identified in approximately 50-60% of resistant cases, which causes steric hindrance that impairs drug binding. For third-generation TKIs like osimertinib, the emergence of the tertiary C797S point mutation presents a major clinical obstacle, as there is a lack of approved targeted therapies for patients harboring this alteration.
Bypass Pathway Activation and Histological Transformation: EGFR-independent mechanisms are a critical source of resistance. These include the amplification of other proto-oncogenes, such as MET (accounting for ~20% of acquired TKI resistance) and ERBB2, as well as the activation of downstream signaling pathways through mutations in PIK3CA, KRAS, or PTEN. In some instances, tumors undergo histological transformation to small-cell lung cancer, rendering EGFR-targeted therapies ineffective.
Primary Resistance and Uncommon Mutations: A substantial portion of patients, estimated at 20-30%, exhibit primary resistance and do not respond to initial EGFR-TKI treatment. Furthermore, the management of patients with uncommon EGFR mutations, such as exon 20 insertions, is challenging due to treatment recommendations being guided mainly by limited prospective and retrospective evidence, making optimal TKI selection difficult.
Cellular and Microenvironmental Factors: Resistance is also influenced by cellular heterogeneity and microenvironmental pressures. Cancer stem cells (CSCs) have been implicated in TKI resistance, and TKI-induced stresses in the tumor microenvironment, adaptive responses like autophagy, and distinct phospholipid signatures in tumor-derived extracellular vesicles are all associated with the development of a resistant phenotype.
Frequently Asked Questions
References
- [1] Ma C, Wei S et al.. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. Journal of thoracic disease. 2011 Mar. 22263058
- [2] Li Y, Mao T et al.. Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. Cell communication and signaling : CCS. 2023 Apr 11. 37041601
- [3] Vidal ÓJ. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation]. Medicina clinica. 2016 Apr. 27426243
- [4] Zhou W, Zhang W et al.. [Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2020 Feb 20. 32093456
- [5] Rebuzzi SE, Alfieri R et al.. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. Critical reviews in oncology/hematology. 2020 Feb. 31785991
- [6] Kijima T, Suzuki M et al.. Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report. Oncology research. 2007. 18196873
- [7] Han SW, Kim TY et al.. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Apr 10. 15710947
- [8] Sebastian M, Schmittel A et al.. First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. European respiratory review : an official journal of the European Respiratory Society. 2014 Mar 1. 24591666
- [9] Liu A, Wang X et al.. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis. BMC cancer. 2024 Nov 12. 39533233
- [10] Tanizaki J, Banno E et al.. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. Lung cancer (Amsterdam, Netherlands). 2016 Nov. 27794398
- [11] Chitnis SP, Wittlinger F et al.. Structure-Activity Relationships of Inactive-Conformation Binding EGFR Inhibitors: Linking the ATP and Allosteric Pockets. Archiv der Pharmazie. 2025 Jul. 40665765
- [12] Shao Y, Lv H et al.. EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties. Oncology letters. 2018 May. 29616128
- [13] Hu P, Han DX et al.. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts. Oncotarget. 2016 Jun 14. 26848869
- [14] Zhong L, Yang J et al.. Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer. Oncotarget. 2017 Feb 21. 28086226
- [15] Zhu H, Cheng H et al.. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. Molecular biology reports. 2012 Apr. 22160570
- [16] Melosky B, Banerji S et al.. Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer. Current oncology (Toronto, Ont.). 2020 Apr. 32489263
- [17] Westover D, Zugazagoitia J et al.. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Jan 1. 29462254
- [18] Yao J, Zhao X et al.. Systematic profiling of chemotherapeutic drug response to EGFR gatekeeper mutation in non-small cell lung cancer. Computational biology and chemistry. 2016 Oct. 27341162
- [19] Bartelink IH, van de Stadt EA et al.. Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients. Pharmaceuticals (Basel, Switzerland). 2022 Jun 27. 35890095
- [20] Ahmad I, Patel HM. Orthoallosteric EGFR-TKIs: A New Paradigm in NSCLC Treatment Strategy Targeting the C797S Mutation. Drug development research. 2025 Feb. 39722446
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
